Form 4: Harmony Biosciences CMO's Equity Transactions

Harmony Biosciences' Chief Medical Officer, Dr. Budur Kumar, reported recent equity transactions including new stock option and RSU grants, alongside the vesting and tax-related disposition of previously awarded restricted stock units.

Summary

• Dr. Budur Kumar, Chief Medical Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported several equity transactions.
• On January 24, 2026, 2,188 shares of common stock vested from restricted stock units, with 1,153 shares withheld by the issuer for income tax obligations at a price of $36.82 per share.
• On January 25, 2026, an additional 2,662 shares of common stock vested from restricted stock units, with 1,372 shares withheld for income tax obligations at a price of $36.82 per share.
• On January 22, 2026, Dr. Kumar was granted 42,600 stock options with an exercise price of $36.76, vesting 25% on January 22, 2027, and quarterly thereafter for four years.
• Also on January 22, 2026, Dr. Kumar received a grant of 12,200 restricted stock units, vesting in four equal annual installments starting January 22, 2027.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects ongoing executive compensation and retention through new equity grants, which aligns management interests with shareholders. The disposition of shares for tax purposes is a standard, neutral event.

Positives

• Grant of 42,600 new stock options to the Chief Medical Officer, indicating continued incentive and alignment with company performance.
• Grant of 12,200 new restricted stock units, further aligning management's interests with long-term shareholder value.
• Vesting of 2,188 and 2,662 previously granted restricted stock units, demonstrating the realization of equity compensation.

Negatives

• Disposition of 1,153 shares and 1,372 shares of common stock, totaling 2,525 shares, to cover income tax withholdings upon RSU vesting, which reduces the direct beneficial ownership.

Future Outlook

The filing details future vesting schedules for stock options and restricted stock units, indicating a long-term incentive structure for the Chief Medical Officer. The stock options will vest 25% on January 22, 2027, with the remainder vesting quarterly until January 22, 2030. The newly granted restricted stock units will vest in four equal annual installments starting January 22, 2027.

Industry Context

NA

Related Party Transactions

• The disposition of 1,153 shares and 1,372 shares of common stock by the issuer to satisfy income tax withholdings upon RSU vesting is a standard practice in equity compensation, effectively a transaction between the company and the reporting person to fulfill tax obligations.

Stakeholder Impact

• Shareholders: The new equity grants align the Chief Medical Officer's interests with long-term shareholder value. The tax-related dispositions are routine and have minimal direct impact on the broader share price.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• Continued vesting of 42,600 stock options, with the next 25% vesting on January 22, 2027, and quarterly thereafter.
• Continued vesting of 12,200 restricted stock units, with the first annual installment vesting on January 22, 2027.
• Continued vesting of previously granted restricted stock units from January 24, 2024, and January 25, 2025, on their respective annual schedules.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation events for a key executive, including new grants and the vesting of existing awards with associated tax withholdings. Such transactions are standard and do not typically signal a fundamental change in the company's prospects or the executive's confidence beyond the established compensation structure. Therefore, it provides no new information to warrant a change from a 'hold' position, assuming the investor's existing thesis remains intact.

Keywords

Harmony Biosciences, HRMY, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Chief Medical Officer, Budur Kumar, Vesting, Tax Withholding